Ultomiris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of rare autoimmune diseases, advancements in monoclonal antibody engineering, expansion of biologics reimbursement frameworks, increased clinician awareness of complement disorders, availability of hospital infusion infrastructure.

The growth in the forecast period can be attributed to increasing investments in rare disease drug development, rising adoption of subcutaneous formulations, expansion of home-based infusion care, growing focus on long-term disease management, increasing demand for reduced treatment burden therapies. Major trends in the forecast period include increasing adoption of long-acting complement inhibitors, rising preference for extended dosing intervals, growing use of targeted autoimmune therapies, expansion of rare disease treatment programs, enhanced focus on patient-centric infusion models.

The growing prevalence of autoimmune disorders is expected to drive the expansion of the ultomiris market in the coming years. Autoimmune disorders occur when the immune system mistakenly targets and damages healthy cells and tissues. This increase in autoimmune disorders is linked to environmental factors, such as exposure to pollutants and chemicals, as well as improved diagnostic methods that identify and treat more patients. Ultomiris addresses autoimmune conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, thereby reducing immune system attacks on the body. For example, according to Arthritis Australia, a non-profit organization based in Australia, in 2025 an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Consequently, the rising prevalence of autoimmune disorders is contributing to the growth of the ultomiris market.

The increase in healthcare spending is also expected to support the growth of the ultomiris market in the future. Healthcare expenditure encompasses financial resources allocated to medical services, infrastructure, insurance, and related activities within a country or region. The growth in healthcare spending is driven by an aging population and the higher prevalence of chronic diseases, which lead to increased costs for ongoing medical management. For ultomiris, healthcare spending covers the cost of the drug, its administration, patient monitoring, and continued research and development to expand its therapeutic applications. For instance, according to the UK’s Office for National Statistics, healthcare expenditure in the USA rose by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth observed in 2022. Therefore, rising healthcare expenditure is expected to support the ultomiris market’s growth.

A major trend in the ultomiris market is obtaining regulatory approval to expand its therapeutic uses and market presence. Drug approval is the process through which regulatory authorities assess and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial results. For example, in March 2024, AstraZeneca, a UK-based pharmaceutical company, received FDA approval for ULTOMIRIS (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for the anti-aquaporin-4 (AQP4) antibody. This approval is significant as ULTOMIRIS is the first long-acting C5 complement inhibitor for NMOSD, demonstrating a 98.6% reduction in relapse risk in clinical trials. By inhibiting the complement system, ULTOMIRIS helps prevent immune attacks on the central nervous system. However, it carries potential risks, including serious meningococcal infections and common side effects such as headache and urinary tract infections.

Major companies operating in the ultomiris market are AstraZeneca Plc.

North America was the largest region in the ultomiris market in 2025. The regions covered in the ultomiris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ultomiris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the ultomiris market by increasing costs associated with imported biologic raw materials, high-purity antibodies, sterile packaging components, and specialized cold-chain distribution systems. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported biologics and advanced formulation inputs, while Asia-Pacific faces elevated costs related to regulatory compliance and manufacturing scale-up. These tariffs are contributing to higher therapy acquisition costs and longer supply lead times. At the same time, they are supporting regional biologics manufacturing expansion, localized fill-finish operations, and strategic partnerships to strengthen domestic production resilience.

The ultomiris market research report is one of a series of new reports that provides ultomiris market statistics, including ultomiris industry global market size, regional shares, competitors with a ultomiris market share, detailed ultomiris market segments, market trends and opportunities, and any further data you may need to thrive in the ultomiris industry. This ultomiris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ultomiris is a prescription drug containing the active ingredient ravulizumab-cwvz, a monoclonal antibody that blocks a part of the immune system called C5 in the complement pathway. It is used to manage certain rare and severe autoimmune conditions by stopping the immune system from attacking healthy cells.

The primary clinical uses of Ultomiris include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired condition in which red blood cells are destroyed prematurely, causing hemolysis and blood clots. Ultomiris is available in different formulations, such as intravenous solutions and subcutaneous forms, and is supplied through hospitals, clinics, as well as retail and specialty pharmacies. It serves various patient groups, including both adults and children.

The ultomiris market consists of sales of ultomiris injections, alpha-1 proteinase inhibitors, subcutaneous injections, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.